MK-1462

MK-1462 is a **synthetic peptide** developed as a balanced dual agonist of the glucagon-like peptide 1 receptor (GLP-1R) and glucagon receptor (GCGR), intended for once daily administration. It is designed for the treatment of **obesity** and **type 2 diabetes** by stimulating both GLP-1R and GCGR, leading to improved glucose metabolism and greater weight loss compared to GLP-1R agonists alone. Preclinical studies have demonstrated its potential to deliver superior metabolic outcomes, including reduced body weight, improved insulin sensitivity, and increased markers of hepatic fatty acid oxidation. MK-1462 shows enhanced solubility, stability, and pharmacokinetic profiles supporting further development. As of the latest reports, it is in preclinical development[1][3][4][5][6][7].